The cytochrome 2C19*2 and*3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention

Thrombosis Research

Volumn 127, Issue 1, 2011, Pages 23-28

  Hwang, Seok Jae ^a   Jeong, Young Hoon ^a   Kim, In Suk ^a   Koh, Jin Sin ^a   Kang, Min Kyung ^a   Park, Yongwhi ^a   Kwak, Choong Hwan ^a   Hwang, Jin Yong ^a  

^a Gyeongsang National University   (South Korea)

Author keywords

clopidogrel; CYP2C193; platelet reactivity

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PROTON PUMP INHIBITOR; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; ELECTIVE SURGERY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; INDEPENDENT VARIABLE; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; SOUTH KOREA; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; ASIAN; BLOOD; BLOOD CLOTTING PARAMETERS; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADENOSINE DIPHOSPHATE; AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650509811     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.10.021     Document Type: Article

References (40)

1. M.E. Bertrand, H.J. Rupprecht, P. Urban, and A.H. Gershlick Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 2000 624 629
2. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, and M.K. Natarajan Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
3. S.R. Steinhubl, P.B. Berger, J.T. Mann III, E.T. Fry, A. DeLago, and C. Wilmer CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention JAMA 288 2002 2411 2420
4. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. López-Sendón, G. Montalescot, and P. Theroux et al; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics, the PCI CLARITY study JAMA 294 2005 1224 1232
5. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
6. T.A. Nguyen, J.G. Diodati, and C. Pharand Resistance to clopidogrel: a review of the evidence J Am Coll Cardiol 45 2005 1157 1164
7. T. Cuisset, C. Frere, J. Quilici, F. Barbou, P.E. Morange, and T. Hovasse High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
8. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, and J.P. Levisay Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000
9. D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, and A. Schömig Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 2009 849 856
10. T. Geisler, D. Grass, B. Bigalke, K. Stellos, T. Drosch, and K. Dietz The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score J Thromb Haemost 6 2008 54 61
11. T. Geisler, E. Schaeffeler, J. Dippon, S. Winter, V. Buse, and C. Bischofs CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation Pharmacogenomics 9 2008 1251 1259
12. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
13. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
14. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Méneveau French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
15. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, and J. Silvain Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
16. D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, and K. Dörrler Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
17. H.G. Xie Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects Clin Pharmacol Ther 62 1997 691 692
18. J.A. Goldstein, T. Ishizaki, K. Chiba, S.M. de Morais, D. Bell, and P.M. Krahn Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations Pharmacogenetics 7 1997 59 64
19. B.L. Chen, W. Zhang, Q. Li, Y.L. Li, Y.J. He, and L. Fan Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms Clin Exp Pharmacol Physiol 35 2008 904 908
20. K.A. Kim, P.W. Park, S.J. Hong, and J.Y. Park The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance Clin Pharmacol Ther 84 2008 236 242
21. Y.H. Jeong, I.S. Kim, B.R. Choi, C.H. Kwak, and J.Y. Hwang The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay Eur Heart J 29 2008 2186 2187
22. H. Fukushima-Uesaka, Y. Saito, K. Maekawa, S. Ozawa, R. Hasegawa, and H. Kajio Genetic variations and haplotypes of CYP2C19 in a Japanese population Drug Metab Pharmacokinet 20 2005 300 307
23. M. Garcia-Barceló, L.Y. Chow, H.F. Kum Chiu, Y.K. Wing, D.T. Shing Lee, and K.L. Lam Frequencies of Defective CYP2C19 Alleles in a Hong Kong Chinese Population: Detection of the Rare Allele CYP2C19*4 Clin Chem 45 1999 2273 2274
24. K.P. Bliden, J. DiChiara, U.S. Tantry, A.K. Bassi, S.K. Chaganti, and P.A. Gurbel Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 49 2007 657 666
25. P.A. Gurbel, K.P. Bliden, K. Guyer, P.W. Cho, K.A. Zaman, and R.P. Kreutz Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study J Am Coll Cardiol 46 2005 1820 1826
26. S.Y. Lee, S.T. Lee, and J.W. Kim Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting J Biochem Mol Biol 40 2007 448 452
27. F. Takakubo, A. Kuwano, and I. Kondo Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese Pharmacogenetics 6 1996 265 267
28. Z.S. Xiao, J.A. Goldstein, H.G. Xie, J. Blaisdell, W. Wang, and C.H. Jiang Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele J Pharmacol Exp Ther 281 1997 604 609
29. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064
30. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
31. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, and T.A. Bass Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
32. T.H. Wang, D.L. Bhatt, and E.J. Topol Aspirin and clopidogrel resistance: an emerging clinical entity Eur Heart J 27 2006 647 654
33. J.M. Lee, S. Park, D.J. Shin, D. Choi, C.Y. Shim, and Y.G. Ko Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans Am J Cardiol 104 2009 46 51
34. M. Lordkipanidze, C. Pharand, T.A. Nguyen, E. Schampaert, and J.G. Diodati Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition Ther Drug Monit 30 2008 372 378
35. H.D. Yoo, S.A. Park, H.Y. Cho, and Y.B. Lee Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects Clin Pharmacol Ther 86 2009 281 284
36. S.R. Mehta, J.F. Tanguay, J.W. Eikelboom, S.S. Jolly, C.D. Joyner, and C.B. Granger Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
37. Y.H. Jeong, I.S. Kim, Y. Park, M.K. Kang, J.S. Koh, and S.J. Hwang Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study JACC Cardiovasc Interv 3 2010 731 741
38. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
39. Y.H. Jeong, S.W. Lee, B.R. Choi, I.S. Kim, M.K. Seo, and C.H. Kwak Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol 53 2009 1101 1109
40. M. Hiratsuka, Y. Hinai, T. Sasaki, Y. Konno, K. Imagawa, and M. Ishikawa Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol Drug Metab Dispos 35 2007 1730 1732